Biotoxtech Co., Ltd. (KOSDAQ:086040)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,620.00
0.00 (0.00%)
At close: Dec 5, 2025

Biotoxtech Statistics

Total Valuation

Biotoxtech has a market cap or net worth of KRW 41.19 billion. The enterprise value is 72.21 billion.

Market Cap 41.19B
Enterprise Value 72.21B

Important Dates

The next estimated earnings date is Friday, March 20, 2026.

Earnings Date Mar 20, 2026
Ex-Dividend Date n/a

Share Statistics

Biotoxtech has 15.72 million shares outstanding. The number of shares has increased by 9.47% in one year.

Current Share Class 15.72M
Shares Outstanding 15.72M
Shares Change (YoY) +9.47%
Shares Change (QoQ) +11.19%
Owned by Insiders (%) 14.74%
Owned by Institutions (%) n/a
Float 10.42M

Valuation Ratios

The trailing PE ratio is 46.83.

PE Ratio 46.83
Forward PE n/a
PS Ratio 0.93
PB Ratio 1.21
P/TBV Ratio 1.01
P/FCF Ratio 15.64
P/OCF Ratio 8.70
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings 82.11
EV / Sales 1.63
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF 27.42

Financial Position

The company has a current ratio of 0.63, with a Debt / Equity ratio of 1.84.

Current Ratio 0.63
Quick Ratio 0.39
Debt / Equity 1.84
Debt / EBITDA n/a
Debt / FCF 23.85
Interest Coverage -1.15

Financial Efficiency

Return on equity (ROE) is -9.79% and return on invested capital (ROIC) is -3.87%.

Return on Equity (ROE) -9.79%
Return on Assets (ROA) -2.78%
Return on Invested Capital (ROIC) -3.87%
Return on Capital Employed (ROCE) -12.48%
Revenue Per Employee 235.06M
Profits Per Employee 4.68M
Employee Count 188
Asset Turnover 0.32
Inventory Turnover 3.00

Taxes

In the past 12 months, Biotoxtech has paid 5.55 billion in taxes.

Income Tax 5.55B
Effective Tax Rate 278.86%

Stock Price Statistics

The stock price has decreased by -18.00% in the last 52 weeks. The beta is 0.22, so Biotoxtech's price volatility has been lower than the market average.

Beta (5Y) 0.22
52-Week Price Change -18.00%
50-Day Moving Average 2,820.10
200-Day Moving Average 2,955.05
Relative Strength Index (RSI) 40.86
Average Volume (20 Days) 19,995

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Biotoxtech had revenue of KRW 44.19 billion and earned 879.45 million in profits.

Revenue 44.19B
Gross Profit 4.37B
Operating Income -6.22B
Pretax Income 1.99B
Net Income 879.45M
EBITDA -1.92B
EBIT -6.22B
Earnings Per Share (EPS) -1.26
Full Income Statement

Balance Sheet

The company has 23.71 billion in cash and 62.82 billion in debt, giving a net cash position of -39.11 billion or -2,487.57 per share.

Cash & Cash Equivalents 23.71B
Total Debt 62.82B
Net Cash -39.11B
Net Cash Per Share -2,487.57
Equity (Book Value) 34.06B
Book Value Per Share 2,690.51
Working Capital -30.31B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.74 billion and capital expenditures -2.10 billion, giving a free cash flow of 2.63 billion.

Operating Cash Flow 4.74B
Capital Expenditures -2.10B
Free Cash Flow 2.63B
FCF Per Share 167.51
Full Cash Flow Statement

Margins

Gross margin is 9.88%, with operating and profit margins of -14.07% and 1.99%.

Gross Margin 9.88%
Operating Margin -14.07%
Pretax Margin 4.50%
Profit Margin 1.99%
EBITDA Margin -4.36%
EBIT Margin -14.07%
FCF Margin 5.96%

Dividends & Yields

Biotoxtech does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -9.47%
Shareholder Yield -9.47%
Earnings Yield 2.14%
FCF Yield 6.39%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Biotoxtech has an Altman Z-Score of 0.24 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 0.24
Piotroski F-Score 6